What should you know about patritumab deruxtecan and lung cancer?

An antibody–drug conjugate combines a targeting antibody with a cancer-killing medicine. The antibody is designed to bind a marker on cancer cells and carry the medicine into the cell. Patritumab deruxtecan targets HER3, a protein that may be present on lung cancer cells. The result is not suitable for everyone, and a laboratory result alone does not determine the whole treatment plan.

Doctors consider the lung cancer type, stage, previous treatments, general health, organ function, and available biomarker information. Genomic tumour profiling may help identify other treatment routes. Lung cancer can also spread beyond the chest, including to the brain, so staging scans guide the discussion.

Ask the oncology team whether this medicine is approved and available for your situation, or whether another option is more appropriate. Discuss how it would be given, how often monitoring is needed, and which symptoms should be reported immediately. Treatment teams may check blood counts, liver function, heart function, and breathing symptoms. Keep a current list of medicines and tell the team about previous lung problems, allergies, and any new cough or breathlessness.

Contact the treatment team urgently for new or worsening breathlessness, persistent cough, fever, chest pain, or reduced oxygen readings if you monitor them. Seek emergency care for severe breathing difficulty, fainting, confusion, or swelling of the face or throat. These symptoms can reflect infection, an infusion reaction, or inflammation affecting the lungs and need prompt assessment.

What marker or test makes this treatment relevant? What benefit are we aiming for? How will lung inflammation and blood-count changes be monitored? Which symptoms require a same-day call? What alternatives, including radiotherapy, chemotherapy, surgery, or supportive care, should we consider?